Actively Recruiting
Effects of Intranasal Oxytocin on Sexual Well-Being in Patients With Arginine Vasopressin Deficiency and Healthy Controls
Led by University Hospital, Basel, Switzerland · Updated on 2025-10-03
42
Participants Needed
1
Research Sites
74 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The study aims to investigate whether intranasal oxytocin (OXT) improves sexual well-being in patients with Arginine Vasopressin Deficiency (AVP-D). The trial consists of two parts: Part A assesses the effect of OXT on sexual well-being and intimacy over a 7-day treatment period in participants in a stable partnership. Part B assesses the effect of a single dose OXT on sexual arousal, fear and empathy in a clinical setting and is designed for single participants and those in partnerships.
CONDITIONS
Official Title
Effects of Intranasal Oxytocin on Sexual Well-Being in Patients With Arginine Vasopressin Deficiency and Healthy Controls
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult healthy volunteers aged 18 years and above
- Matched for age, sex, BMI, and menopause/hormonal contraceptives to patients
- No medication, except hormonal contraception
- At least mild impairment in sexual function and satisfaction, defined as an ASEX-score 6510 points and an NSSS-S score 64 48 points
- Only Part A: Participants must be sexually active (at least once a week sexual intercourse) and in a current partnership for at least 6 months
- Adult patients aged 18 years and above, with a confirmed diagnosis of AVP deficiency based on established criteria
- Stable hormone replacement therapy for at least three months with desmopressin and, in case of additional anterior pituitary deficiencies, with the respective substitution therapies
- At least mild impairment in sexual function and satisfaction, defined as an ASEX-score 6510 points and an NSSS-S score 64 48 points
- Only Part A: Participants must be sexually active (at least once a week sexual intercourse) and in a current partnership for at least 6 months
You will not qualify if you...
- Pregnancy and breastfeeding within the last eight weeks
- Participation in a trial with investigational drugs within 30 days
- Active substance use disorder within the last six months
- Consumption of alcoholic beverages >15 drinks/week
- Current or previous psychotic disorder (e.g., schizophrenia)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University Hospital Basel
Basel, Switzerland, 4031
Actively Recruiting
Research Team
M
Mirjam Christ-Crain, Prof. MD
CONTACT
C
Cemile Bathelt
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here